Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UNITED THERAPEUTICS (UTHR) EBITDA: 2009-2024

Historic EBITDA for UNITED THERAPEUTICS (UTHR) over the last 16 years, with Dec 2024 value amounting to $1.4 billion.

  • UNITED THERAPEUTICS's EBITDA rose 13.23% to $388.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year increase of 16.73%. This contributed to the annual value of $1.4 billion for FY2024, which is 16.21% up from last year.
  • According to the latest figures from FY2024, UNITED THERAPEUTICS's EBITDA is $1.4 billion, which was up 16.21% from $1.2 billion recorded in FY2023.
  • Over the past 5 years, UNITED THERAPEUTICS's EBITDA peaked at $1.4 billion during FY2024, and registered a low of $555.9 million during FY2021.
  • Its 3-year average for EBITDA is $1.2 billion, with a median of $1.2 billion in 2023.
  • As far as peak fluctuations go, UNITED THERAPEUTICS's EBITDA surged by 416.42% in 2020, and later declined by 6.35% in 2021.
  • Over the past 5 years, UNITED THERAPEUTICS's EBITDA (Yearly) stood at $593.6 million in 2020, then decreased by 6.35% to $555.9 million in 2021, then skyrocketed by 76.24% to $979.7 million in 2022, then climbed by 20.95% to $1.2 billion in 2023, then increased by 16.21% to $1.4 billion in 2024.